Research programme: sleep disorder therapeutics - ServierAlternative Names: S 41150
Latest Information Update: 24 Apr 2016
At a glance
- Originator Servier
- Mechanism of Action Histamine H3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sleep disorders
Most Recent Events
- 14 Apr 2010 No development reported - Preclinical for Sleep disorders in France (PO)
- 07 Nov 2007 Preclinical trials in Sleep disorders in France (PO)